Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095

被引：0
|
作者：
Ali Afshar-Oromieh
Uwe Haberkorn
Christian Zechmann
Thomas Armor
Walter Mier
Fabian Spohn
Nils Debus
Tim Holland-Letz
John Babich
Clemens Kratochwil
机构：
[1] Heidelberg University Hospital,Department of Nuclear Medicine
[2] German Cancer Research Center,Clinical Cooperation Unit Nuclear Medicine
[3] Progenics Pharmaceuticals,Department of Biostatistics
[4] Inc.,Division of Radiopharmaceutical Sciences, Department of Radiology
[5] German Cancer Research Center,Citigroup Biomedical Imaging Center
[6] Weill Cornell Medicine,Meyer Cancer Center
[7] Weill Cornell Medicine,undefined
[8] Weill Cornell Medicine,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2017年 / 44卷
关键词：
Prostate cancer; PSMA; Prostate-specific membrane antigen; Endoradiotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：950 / 959
页数：9
相关论文
共 50 条
  • [21] Value proposition of PSMA-targeted α-particle radioligand therapy in metastatic prostate cancer
    Jadvar, Hossein
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (01) : 8 - 10
  • [22] Antitumor activity of repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
    Rahbar, Kambiz
    Braeuer, Axel
    Yordanova, Anna
    Boegemann, Martin
    Hauser, Stefan
    Eveslage, Maria
    Essler, Markus
    Schafers, Michael
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [23] 213Bi-labeled PSMA-targeting agents for alpha radionuclide therapy of prostate cancer
    Chatalic, Kristell
    Nonnekens, Julie
    Bruchertseifer, Frank
    Morgenstern, Alfred
    Schottelius, Margret
    Wester, Hans
    van Weerden, Wytske
    Boerman, Otto
    de Jong, Marion
    Heskamp, Sandra
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [24] Investigation of the Molecular Design of PSMA-targeting Radioligands for Imaging of Prostate Cancer
    Lundmark, F.
    Olanders, G.
    Rinne, S. S.
    Abouzayed, A.
    Orlova, A.
    Rosenstrom, U.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S18 - S19
  • [25] Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment
    Ruigrok, Eline A. M.
    Verkaik, Nicole S.
    de Blois, Erik
    de Ridder, Corrina
    Stuurman, Debra
    Roobol, Stefan J.
    Van Gent, Dik C.
    de Jong, Marion
    Van Weerden, Wytske M.
    Nonnekens, Julie
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (14)
  • [26] Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [177Lu]Ludotadipep in Patients With Metastatic Castration-Resistant Prostate Cancer
    Ha, Seunggyun
    Hyun, O. Joo
    Park, Chansoo
    Boo, Sun Ha
    Yoo, Ie Ryung
    Moon, Hyong Woo
    Chi, Dae Yoon
    Lee, Ji Youl
    KOREAN JOURNAL OF RADIOLOGY, 2024, 25 (02) : 179 - 188
  • [27] PSMA-targeted radioligand therapy in prostate cancer
    Heck, M. M.
    Retz, M.
    Tauber, R.
    Knorr, K.
    Kratochwil, C.
    Eiber, M.
    UROLOGE, 2017, 56 (01): : 32 - 39
  • [28] PSMA radioligand therapy in patients with advanced prostate cancer
    Boegemann, M.
    Herrmann, K.
    Radtke, J. P.
    Rahbar, K.
    UROLOGE, 2020, 59 (06): : 680 - 686
  • [29] 177Lu-PSMA-I&T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer:FirstClinical trialin Asia
    Bu, Ting
    Zhang, Pengjun
    Zang, Shiming
    Zhang, Lulu
    Wang, Feng
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [30] Evaluation of a Long-circulating PSMA-targeting Peptide in a Xenograft Model of Bone Metastatic Prostate Cancer.
    Lo, W.
    Huang, Y.
    Chen, M.
    Lu, A.
    Wang, S.
    Chen, L.
    Farn, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S442 - S442
12345